London Underground Study - Health Effects of Particulate Matter
Launched by IMPERIAL COLLEGE LONDON · Oct 28, 2020
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria for both groups:
- • Give informed consent
- • London resident
- For participants with COPD:
- • GOLD stage 2 COPD (FEV1/FVC\<70%; 50%\>FEV1\<80% predicted), GOLD stage 3 COPD (FEV1/FVC\<70%; 30%\>FEV1\<50%) and GOLD stage 4 (FEV1/FVC\<70%;FEV1\<30%)
- • No history of ischaemic heart disease
- For healthy volunteers:
- • No history of ischaemic heart disease.
- • Normal lung function with no evidence of airflow obstruction.
- Exclusion Criteria for both participants with COPD and healthy volunteers:
- • Those with unstable ischaemic heart disease or COPD.
- • Current smokers and those who are ex-smokers of \<12 months duration.
- • Those who work in the London Underground or are occupationally exposed to - - high levels of vehicle traffic exposure on a frequent basis.
- • Those who cannot walk for 30 mins.
- • Involvement in another research study
- • Those unable to give consent.
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Frank Kelly
Principal Investigator
Imperial College London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials